EUVIMEDEUVIMED entdecken
Open Access

Comparative efficacy of CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib in HR+/HER2- advanced breast cancer

Bo Hou, Yu Zhang

American Journal of Cancer Research · 2026 · 16 (5) · 1805-1816

DOI: 10.62347/hykp5700 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Cancer Research, 2026. Verfasst von Bo Hou und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, The First People's Hospital of Chun'an County Chun'an 311700, Zhejiang, China. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

CDK4/6 inhibitorshormone receptor-positive breast cancerreal-world progression-free survival (rwPFS)

Autor:innen und Institutionen

  • Department of Medical Oncology, The First People's Hospital of Chun'an County Chun'an 311700, Zhejiang, China.
  • Department of Pharmacy, Ganzhou Fifth People's Hospital Ganzhou 341000, Jiangxi, China.

Zitieren

APA

Hou, B., & Zhang, Y. (2026). Comparative efficacy of CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib in HR+/HER2- advanced breast cancer. American Journal of Cancer Research, 16(5), 1805-1816. https://doi.org/10.62347/hykp5700

Vancouver

Hou B, Zhang Y. Comparative efficacy of CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib in HR+/HER2- advanced breast cancer. American Journal of Cancer Research. 2026;16(5):1805-1816. doi:10.62347/hykp5700

BibTeX
@article{Hou2026,
  author = {Hou, Bo and Zhang, Yu},
  title = {Comparative efficacy of CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib in HR+/HER2- advanced breast cancer},
  journal = {American Journal of Cancer Research},
  year = {2026},
  volume = {16},
  number = {5},
  pages = {1805--1816},
  doi = {10.62347/hykp5700}
}
Kostenlos starten →